Nguyen and colleagues used a rat model of repeated neonatal midazolam exposure and examined outcomes at several developmental stages. The authors measured neurotransmitters in the prefrontal cortex alongside molecular and behavioral outcomes. Looking across ages allowed the group to ask whether an observed difference persisted or changed direction.
At postnatal day 28, the exposed animals had lower levels of the dopamine metabolites DOPAC and HVA. At day 60, dopamine itself was lower. The study also assessed social behavior using separate sociability and social-novelty tests. These behavioral tasks answer different questions from the neurochemical assays.
Specify the tissue, developmental stage and assay whenever citing the dopamine result. A tissue concentration does not directly measure neurotransmitter release or explain the behavior of an individual animal. The experimental exposure is informative about timing in that model. A human neonatal case requires its own dose history, clinical context and developmental follow-up because critical illness and other treatments can influence the same outcomes.